DD273839A5 - Verfahren zur herstellung neuer insulinderivate - Google Patents

Verfahren zur herstellung neuer insulinderivate Download PDF

Info

Publication number: DD273839A5
Authority: DD; German Democratic Republic
Prior art keywords: human insulin; gln; lys; insulin; arg
Prior art date: 1986-07-21

Application number

DD87305161A

Other languages

German (de)

English (en)

Inventor

Jan Markussen

Kjeld Norris

Liselotte Langkjaer

Original Assignee

��@��@�a�k��

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-07-21

Filing date

1987-07-20

Publication date

1989-11-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8123250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DD273839(A5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1987-07-20 Application filed by ��@��@�a�k�� filed Critical ��@��@�a�k��

1989-11-29 Publication of DD273839A5 publication Critical patent/DD273839A5/de

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 184
238000000034 method Methods 0.000 title claims abstract description 30
238000002360 preparation method Methods 0.000 title claims abstract description 25
230000008569 process Effects 0.000 title claims abstract description 8
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Natural products C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims abstract description 94
102000004877 Insulin Human genes 0.000 claims abstract description 86
108090001061 Insulin Proteins 0.000 claims abstract description 86
229940125396 insulin Drugs 0.000 claims abstract description 81
150000001875 compounds Chemical class 0.000 claims abstract description 72
229940024606 amino acid Drugs 0.000 claims abstract description 32
235000001014 amino acid Nutrition 0.000 claims abstract description 32
125000000539 amino acid group Chemical group 0.000 claims abstract description 28
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 14
125000003277 amino group Chemical group 0.000 claims abstract description 13
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims abstract description 9
239000004473 Threonine Substances 0.000 claims abstract description 7
150000001408 amides Chemical group 0.000 claims abstract description 7
229960002898 threonine Drugs 0.000 claims abstract description 7
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims description 148
101000976075 Homo sapiens Insulin Proteins 0.000 claims description 147
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 115
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 71
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 64
150000001413 amino acids Chemical class 0.000 claims description 30
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 18
-1 hSer A21 Chemical compound 0.000 claims description 13
239000002243 precursor Substances 0.000 claims description 11
238000006243 chemical reaction Methods 0.000 claims description 10
230000007935 neutral effect Effects 0.000 claims description 9
229960001230 asparagine Drugs 0.000 claims description 7
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims description 7
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 6
125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 claims description 6
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
235000009582 asparagine Nutrition 0.000 claims description 6
210000004899 c-terminal region Anatomy 0.000 claims description 6
239000004475 Arginine Substances 0.000 claims description 5
108090000631 Trypsin Proteins 0.000 claims description 5
102000004142 Trypsin Human genes 0.000 claims description 5
235000009697 arginine Nutrition 0.000 claims description 5
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims description 5
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims description 5
239000012588 trypsin Substances 0.000 claims description 5
229930064664 L-arginine Natural products 0.000 claims description 4
235000014852 L-arginine Nutrition 0.000 claims description 4
125000004185 ester group Chemical group 0.000 claims description 4
150000003951 lactams Chemical class 0.000 claims description 4
230000001810 trypsinlike Effects 0.000 claims description 4
108090000790 Enzymes Proteins 0.000 claims description 3
102000004190 Enzymes Human genes 0.000 claims description 3
239000004472 Lysine Substances 0.000 claims description 3
108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 3
235000004554 glutamine Nutrition 0.000 claims description 3
235000018977 lysine Nutrition 0.000 claims description 3
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
108090000765 processed proteins & peptides Proteins 0.000 claims description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
125000003545 alkoxy group Chemical group 0.000 claims description 2
125000000217 alkyl group Chemical group 0.000 claims description 2
239000003054 catalyst Substances 0.000 claims description 2
229910052739 hydrogen Inorganic materials 0.000 claims description 2
239000001257 hydrogen Substances 0.000 claims description 2
125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
239000012634 fragment Substances 0.000 claims 2
239000011701 zinc Substances 0.000 abstract description 17
230000002035 prolonged effect Effects 0.000 abstract description 16
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract description 15
230000009471 action Effects 0.000 abstract description 15
229910052725 zinc Inorganic materials 0.000 abstract description 15
239000000203 mixture Substances 0.000 abstract description 9
102000007079 Peptide Fragments Human genes 0.000 abstract description 4
108010033276 Peptide Fragments Proteins 0.000 abstract description 4
125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 abstract description 3
238000002156 mixing Methods 0.000 abstract description 3
101000729818 Bacillus licheniformis Glutamate racemase Proteins 0.000 abstract 1
125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 abstract 1
239000000243 solution Substances 0.000 description 42
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 28
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 22
PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 17
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 13
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
239000000725 suspension Substances 0.000 description 12
239000013078 crystal Substances 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
230000000694 effects Effects 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 7
206010012601 diabetes mellitus Diseases 0.000 description 7
238000003786 synthesis reaction Methods 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
125000002843 carboxylic acid group Chemical group 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
239000004026 insulin derivative Substances 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
108010005991 Pork Regular Insulin Proteins 0.000 description 5
239000002253 acid Substances 0.000 description 5
125000004432 carbon atom Chemical group C* 0.000 description 5
238000002425 crystallisation Methods 0.000 description 5
230000008025 crystallization Effects 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
108010076181 Proinsulin Proteins 0.000 description 4
102000007327 Protamines Human genes 0.000 description 4
108010007568 Protamines Proteins 0.000 description 4
240000004808 Saccharomyces cerevisiae Species 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 4
230000008859 change Effects 0.000 description 4
239000003814 drug Substances 0.000 description 4
238000001962 electrophoresis Methods 0.000 description 4
RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 4
230000005012 migration Effects 0.000 description 4
238000013508 migration Methods 0.000 description 4
239000002773 nucleotide Substances 0.000 description 4
125000003729 nucleotide group Chemical group 0.000 description 4
229940048914 protamine Drugs 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000011550 stock solution Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
239000013589 supplement Substances 0.000 description 4
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
VVQIIIAZJXTLRE-QMMMGPOBSA-N (2s)-2-amino-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound CC(C)(C)OC(=O)NCCCC[C@H](N)C(O)=O VVQIIIAZJXTLRE-QMMMGPOBSA-N 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
150000008575 L-amino acids Chemical group 0.000 description 3
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
239000012736 aqueous medium Substances 0.000 description 3
239000000872 buffer Substances 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 3
239000000047 product Substances 0.000 description 3
125000006239 protecting group Chemical group 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
230000009467 reduction Effects 0.000 description 3
238000003756 stirring Methods 0.000 description 3
235000008521 threonine Nutrition 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
229960003767 alanine Drugs 0.000 description 2
125000003368 amide group Chemical group 0.000 description 2
239000003708 ampul Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
235000010633 broth Nutrition 0.000 description 2
230000007423 decrease Effects 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
229940079593 drug Drugs 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
230000002218 hypoglycaemic effect Effects 0.000 description 2
238000011835 investigation Methods 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
238000011068 loading method Methods 0.000 description 2
230000007774 longterm Effects 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
239000001103 potassium chloride Substances 0.000 description 2
235000011164 potassium chloride Nutrition 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
239000003223 protective agent Substances 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
235000004400 serine Nutrition 0.000 description 2
229960001153 serine Drugs 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
241000894007 species Species 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
239000004474 valine Substances 0.000 description 2
150000003751 zinc Chemical class 0.000 description 2
239000011592 zinc chloride Substances 0.000 description 2
235000005074 zinc chloride Nutrition 0.000 description 2
UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
LRZSAGKIMYFLHY-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;dihydrate Chemical compound O.O.OC(=O)CC(O)(C(O)=O)CC(O)=O LRZSAGKIMYFLHY-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241000590035 Achromobacter lyticus Species 0.000 description 1
FJVAQLJNTSUQPY-CIUDSAMLSA-N Ala-Ala-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN FJVAQLJNTSUQPY-CIUDSAMLSA-N 0.000 description 1
108010065691 Biphasic Insulins Proteins 0.000 description 1
241000283725 Bos Species 0.000 description 1
101001011741 Bos taurus Insulin Proteins 0.000 description 1
108010075254 C-Peptide Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
108010016626 Dipeptides Proteins 0.000 description 1
241001061260 Emmelichthys struhsakeri Species 0.000 description 1
XIPZDANNDPMZGQ-WHFBIAKZSA-N Gln-Cys Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(O)=O XIPZDANNDPMZGQ-WHFBIAKZSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
229920001202 Inulin Polymers 0.000 description 1
102000005237 Isophane Insulin Human genes 0.000 description 1
108010081368 Isophane Insulin Proteins 0.000 description 1
UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
239000005639 Lauric acid Substances 0.000 description 1
108010053229 Lysyl endopeptidase Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
241000201776 Steno Species 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000004075 alteration Effects 0.000 description 1
125000006242 amine protecting group Chemical group 0.000 description 1
IVHKZGYFKJRXBD-UHFFFAOYSA-N amino carbamate Chemical compound NOC(N)=O IVHKZGYFKJRXBD-UHFFFAOYSA-N 0.000 description 1
239000002152 aqueous-organic solution Substances 0.000 description 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
108010068380 arginylarginine Proteins 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
239000000189 biphasic insulin Substances 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
239000001639 calcium acetate Substances 0.000 description 1
229960005147 calcium acetate Drugs 0.000 description 1
235000011092 calcium acetate Nutrition 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
229960002743 glutamine Drugs 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
229940029339 inulin Drugs 0.000 description 1
JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000000962 organic group Chemical group 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000011146 sterile filtration Methods 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
239000012085 test solution Substances 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1
239000004246 zinc acetate Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Diabetes (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Endocrinology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Obesity (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Emergency Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Toxicology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DD87305161A 1986-07-21 1987-07-20 Verfahren zur herstellung neuer insulinderivate DD273839A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DK347086A DK347086D0 (da)	1986-07-21	1986-07-21	Novel peptides

Publications (1)

Publication Number	Publication Date
DD273839A5 true DD273839A5 (de)	1989-11-29

Family

ID=8123250

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD87305161A DD273839A5 (de)	1986-07-21	1987-07-20	Verfahren zur herstellung neuer insulinderivate

Country Status (20)

Country	Link
EP (1)	EP0254516B1 (pt)
JP (1)	JPS6399096A (pt)
KR (1)	KR880001701A (pt)
CN (1)	CN87104988A (pt)
AT (1)	ATE99699T1 (pt)
AU (1)	AU612324B2 (pt)
DD (1)	DD273839A5 (pt)
DE (2)	DE3788684T2 (pt)
DK (1)	DK347086D0 (pt)
ES (1)	ES2061504T3 (pt)
FI (1)	FI873185A7 (pt)
HU (1)	HU203371B (pt)
IL (1)	IL83243A (pt)
MY (1)	MY102873A (pt)
NL (1)	NL300018I1 (pt)
NO (1)	NO170978C (pt)
NZ (1)	NZ221130A (pt)
PT (1)	PT85355B (pt)
YU (1)	YU135387A (pt)
ZA (1)	ZA875295B (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI884914A0 (fi) *	1987-02-25	1988-10-24	Novo Industri As	Nya insulinderivat.
DK336188D0 (da) *	1988-06-20	1988-06-20	Nordisk Gentofte	Propeptider
KR900701842A (ko) *	1988-07-20	1990-12-04	헨리 브뢰늄	인간 인슐린 동족체와 그를 포함하는 제제
DE3827533A1 (de) *	1988-08-13	1990-02-15	Hoechst Ag	Pharmazeutische zubereitung zur behandlung des diabetes mellitus
DE3837825A1 (de) *	1988-11-08	1990-05-10	Hoechst Ag	Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
KR910700262A (ko) *	1988-12-23	1991-03-14	안네 제케르	사람 인슐린 유사체
US5716927A (en) *	1988-12-23	1998-02-10	Novo Nordisk A/S	Insulin analogs having a modified B-chain
US5514646A (en) *	1989-02-09	1996-05-07	Chance; Ronald E.	Insulin analogs modified at position 29 of the B chain
DK134189D0 (da) *	1989-03-20	1989-03-20	Nordisk Gentofte	Insulinforbindelser
DE3936876A1 (de) *	1989-11-06	1991-05-23	Hoechst Ag	Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5474978A (en) *	1994-06-16	1995-12-12	Eli Lilly And Company	Insulin analog formulations
US5693609A (en) *	1994-11-17	1997-12-02	Eli Lilly And Company	Acylated insulin analogs
US7316999B2 (en)	2000-06-02	2008-01-08	Novo Nordisk A/S	Glucose dependent release of insulin from glucose sensing insulin derivatives
DE10114178A1 (de)	2001-03-23	2002-10-10	Aventis Pharma Gmbh	Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE60236014D1 (de)	2001-11-19	2010-05-27	Novo Nordisk As	Verfahren zur herstellung von insulinverbindungen
GB0206792D0 (en)	2002-03-22	2002-05-01	Leuven K U Res & Dev	Normoglycemia
DE10227232A1 (de)	2002-06-18	2004-01-15	Aventis Pharma Deutschland Gmbh	Saure Insulinzubereitungen mit verbesserter Stabilität
RU2381103C2 (ru)	2003-06-27	2010-02-10	Ново Нордиск А/С	Контейнер для жидких фармацевтических композиций с высокими влагозащитными свойствами
ATE483580T1 (de)	2003-12-22	2010-10-15	Novo Nordisk As	Durchsichtiger, flexibler, undurchlässiger kunststoffbehälter zur lagerung von pharmazeutischen flüssigkeiten
EP2033662B1 (en)	2004-01-21	2012-10-17	Novo Nordisk Health Care AG	Transglutaminase mediated conjugation of peptides
DE102006031955A1 (de) *	2006-07-11	2008-01-17	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
DE102006031962A1 (de)	2006-07-11	2008-01-17	Sanofi-Aventis Deutschland Gmbh	Amidiertes Insulin Glargin
WO2008049711A1 (en)	2006-10-27	2008-05-02	Novo Nordisk A/S	Peptide extended insulins
EP2229406B1 (de) *	2008-01-09	2015-04-22	Sanofi-Aventis Deutschland GmbH	Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil
CN102007143B (zh)	2008-01-09	2015-08-26	塞诺菲-安万特德国有限公司	具有超延迟时效特征的新型胰岛素衍生物
CN102037008B (zh)	2008-03-18	2016-08-31	诺沃-诺迪斯克有限公司	蛋白酶稳定化的、酰化胰岛素类似物
TWI451876B (zh)	2008-06-13	2014-09-11	Lilly Co Eli	聚乙二醇化之離脯胰島素化合物
RU2458989C1 (ru)	2008-08-07	2012-08-20	Байокон Лимитид	Способ получения аналогов инсулина из их соответствующих предшественников (варианты)
CN102256618A (zh)	2008-10-17	2011-11-23	赛诺菲-安万特德国有限公司	胰岛素和glp-1激动剂的组合
PL2451437T3 (pl)	2009-07-06	2017-05-31	Sanofi-Aventis Deutschland Gmbh	Wodne preparaty insuliny zawierające metioninę
WO2011003820A1 (de) *	2009-07-06	2011-01-13	Sanofi-Aventis Deutschland Gmbh	Hitze- und schüttelstabile insulinzubereitungen
NZ599847A (en)	2009-11-13	2013-09-27	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a glp-1 agonist and methionine
TR201809460T4 (tr)	2009-11-13	2018-07-23	Sanofi Aventis Deutschland	Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
EP2460527A1 (en)	2010-01-21	2012-06-06	Sanofi	Pharmaceutical composition for treating a metabolic syndrome
TW201141513A (en)	2010-04-14	2011-12-01	Sanofi Aventis	Insulin-siRNA conjugates
WO2012028172A1 (en)	2010-08-30	2012-03-08	Sanofi-Aventis Deutschland Gmbh	Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
EP2548570A1 (en)	2011-07-19	2013-01-23	Sanofi	Pharmaceutical composition for treating a metabolic syndrome
AR087693A1 (es)	2011-08-29	2014-04-09	Sanofi Aventis Deutschland	Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9481721B2 (en)	2012-04-11	2016-11-01	Novo Nordisk A/S	Insulin formulations
US9656017B2 (en)	2014-06-20	2017-05-23	Howard E. Greene	Infusion delivery devices and methods
PE20171622A1 (es)	2014-12-12	2017-11-02	Sanofi Aventis Deutschland	Formulacion de relacion fija de insulina glargina/lixisenatida
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
TWI700091B (zh)	2016-12-16	2020-08-01	丹麥商諾佛儂迪克股份有限公司	含胰島素醫藥組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3033127A1 (de) *	1980-09-03	1982-04-08	Hoechst Ag, 6000 Frankfurt	Neue analoga des insulins
DE3327709A1 (de) *	1983-07-29	1985-02-07	Hoechst Ag, 6230 Frankfurt	Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
DE3333640A1 (de) *	1983-09-17	1985-04-25	Hoechst Ag, 6230 Frankfurt	Verfahren zur herstellung von insulin-derivaten, deren b-kette c-terminal verlaengert ist, neue basisch modifizierte insulin-derivate diese enthaltende mittel und ihre verwendung
DK113585D0 (da) *	1985-03-12	1985-03-12	Novo Industri As	Nye peptider
DK119785D0 (da) *	1985-03-15	1985-03-15	Nordisk Gentofte	Insulinpraeparat

1986
- 1986-07-21 DK DK347086A patent/DK347086D0/da not_active Application Discontinuation
1987
- 1987-07-20 DE DE3788684T patent/DE3788684T2/de not_active Expired - Lifetime
- 1987-07-20 MY MYPI87001062A patent/MY102873A/en unknown
- 1987-07-20 FI FI873185A patent/FI873185A7/fi not_active Application Discontinuation
- 1987-07-20 IL IL83243A patent/IL83243A/xx not_active IP Right Cessation
- 1987-07-20 AT AT87306405T patent/ATE99699T1/de not_active IP Right Cessation
- 1987-07-20 KR KR1019870007832A patent/KR880001701A/ko not_active Ceased
- 1987-07-20 NZ NZ221130A patent/NZ221130A/xx unknown
- 1987-07-20 PT PT85355A patent/PT85355B/pt not_active IP Right Cessation
- 1987-07-20 CN CN198787104988A patent/CN87104988A/zh active Pending
- 1987-07-20 YU YU01353/87A patent/YU135387A/xx unknown
- 1987-07-20 DD DD87305161A patent/DD273839A5/de not_active IP Right Cessation
- 1987-07-20 HU HU873343A patent/HU203371B/hu not_active IP Right Cessation
- 1987-07-20 AU AU75916/87A patent/AU612324B2/en not_active Ceased
- 1987-07-20 EP EP87306405A patent/EP0254516B1/en not_active Expired - Lifetime
- 1987-07-20 DE DE2000175024 patent/DE10075024I1/de active Pending
- 1987-07-20 ZA ZA875295A patent/ZA875295B/xx unknown
- 1987-07-20 ES ES87306405T patent/ES2061504T3/es not_active Expired - Lifetime
- 1987-07-20 NO NO873018A patent/NO170978C/no unknown
- 1987-07-21 JP JP62180168A patent/JPS6399096A/ja active Pending
2000
- 2000-09-15 NL NL300018C patent/NL300018I1/nl unknown

Also Published As

Publication number	Publication date
FI873185A0 (fi)	1987-07-20
NO873018D0 (no)	1987-07-20
DK347086D0 (da)	1986-07-21
AU7591687A (en)	1988-01-28
IL83243A (en)	1993-01-14
PT85355A (en)	1987-08-01
IL83243A0 (en)	1987-12-31
DE3788684D1 (de)	1994-02-17
DE3788684T2 (de)	1994-05-19
KR880001701A (ko)	1988-04-26
JPS6399096A (ja)	1988-04-30
NO170978C (no)	1993-01-06
CN87104988A (zh)	1988-03-02
EP0254516A2 (en)	1988-01-27
EP0254516B1 (en)	1994-01-05
FI873185L (fi)	1988-01-22
NO170978B (no)	1992-09-28
ZA875295B (en)	1988-01-21
NZ221130A (en)	1990-08-28
DE10075024I1 (de)	2000-11-09
NO873018L (no)	1988-01-22
AU612324B2 (en)	1991-07-11
YU135387A (en)	1988-10-31
MY102873A (en)	1993-03-31
EP0254516A3 (en)	1990-06-27
HU203371B (en)	1991-07-29
ATE99699T1 (de)	1994-01-15
PT85355B (pt)	1990-04-30
HUT45271A (en)	1988-06-28
NL300018I1 (nl)	2000-11-01
FI873185A7 (fi)	1988-01-22
ES2061504T3 (es)	1994-12-16

Legal Events

Date	Code	Title	Description
2000-02-17	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
DD273839A5 (de)	1989-11-29	Verfahren zur herstellung neuer insulinderivate
DE3685668T2 (de)	1993-01-14	Peptide.
DE69722397T2 (de)	2004-04-01	Insulin-derivate und ihre verwendung
EP0132769B1 (de)	1988-01-07	Pharmazeutisches Mittel zur Behandlung des Diabetes mellitus
EP0885961B1 (de)	2004-12-01	Neue Insulinderivate mit schnellem Wirkungseintritt
EP0132770B1 (de)	1987-09-16	Neue Insulin-Derivate, Verfahren zu deren Herstellung und deren Verwendung sowie pharmazeutische Mittel zur Behandlung des Diabetes mellitus
EP2229407B1 (de)	2016-11-16	Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil
US4946828A (en)	1990-08-07	Novel insulin peptides
DE3880346T2 (de)	1993-07-29	Insulinderivate.
EP2229406B1 (de)	2015-04-22	Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil
DE69632224T2 (de)	2005-04-14	Reduzierung von Gelation von Fettsäureacylierten Proteinen unter Nutzung von Zitratpuffer
NZ238718A (en)	1992-06-25	Insulin analogue and its preparation
DE102008003568A1 (de)	2009-07-16	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003566A1 (de)	2009-07-16	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
EP0140084A1 (de)	1985-05-08	Verfahren zur Herstellung von Insulin-Derivaten, deren B-Kette C-terminal verlängert ist, neue basisch modifizierte Insulin-Derivate, diese enthaltende Mittel und ihre Verwendung
KR20160065126A (ko)	2016-06-08	인슐린 유사체의 신규한 유도체
EP0427162B1 (de)	1996-05-08	Neue Insulinderivate, Verfahren zu deren Herstellung, ihre Verwendung und eine sie enthaltende pharmazeutische Zubereitung
EP1084248A2 (de)	2001-03-21	Neue insulinanaloga mit erhöhter zinkbindung
EP0622376B1 (de)	2001-08-08	Amorphe monosphärische Formen von Insulinderivaten
DE102008025007A1 (de)	2009-11-26	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil